{"organizations": [], "uuid": "6beebca346f30514cb8287aa9cb45bf9418d6320", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/09/22/idUSFWN11R00O20150922", "country": "US", "title": "BRIEF-Galapagos presents pre-clinical and phase 1 results with autotaxin inhibitor GLPG1690", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "BRIEF-Galapagos presents pre-clinical and phase 1 results with autotaxin inhibitor GLPG1690 | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-09-22T09:38:00.000+03:00", "replies_count": 0, "uuid": "6beebca346f30514cb8287aa9cb45bf9418d6320"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/09/22/idUSFWN11R00O20150922", "ord_in_thread": 0, "title": "BRIEF-Galapagos presents pre-clinical and phase 1 results with autotaxin inhibitor GLPG1690", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Sept 22 Galapagos NV :\n* Presents promising pre-clinical and phase 1 results with autotaxin inhibitor GLPG1690 at the European Respiratory Society (ERS) Annual Meeting in Amsterdam, Netherlands\n* Also presents topline results with GLPG1690 in phase 1 in healthy human volunteers\n* Expects to file an exploratory phase 2 study in idiopathic pulmonary fibrosis before year end\nSource text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2015-09-22T09:38:00.000+03:00", "crawled": "2015-09-22T08:46:04.580+03:00", "highlightTitle": ""}